Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06317558
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-03-12
Brief Title:
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Study Overview
Official Title:
Real-world Clinical Outcomes of Neoadjuvant Immunotherapy in NSCLC Patients A Retrospective Multi-center Cohort Study NeoIM-Lung
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NeoIM-Lung
Brief Summary:
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer NSCLC patients using the real-world data The main questions it aims to answer are
What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment
How to determine the subgroups of patients benefit from neoadjuvant immunotherapy Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data
What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment
How to determine the subgroups of patients benefit from neoadjuvant immunotherapy Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data
Detailed Description:
The objective of this observational study is to assess the effectiveness and long-term clinical outcomes of various neoadjuvant immunotherapies in patients with non-small cell lung cancer NSCLC using the real-world data The primary inquiries it seeks to address include
What is the optimal strategy for utilizing immune checkpoint inhibitors as neoadjuvant therapy
How can we identify specific patient subgroups that derive the greatest benefit from neoadjuvant immunotherapy Participants will undergo neoadjuvant immunotherapy and the study will meticulously analyze real-world data to provide insights into these pivotal questions contributing to the refinement of treatment strategies and patient care in NSCLC management
What is the optimal strategy for utilizing immune checkpoint inhibitors as neoadjuvant therapy
How can we identify specific patient subgroups that derive the greatest benefit from neoadjuvant immunotherapy Participants will undergo neoadjuvant immunotherapy and the study will meticulously analyze real-world data to provide insights into these pivotal questions contributing to the refinement of treatment strategies and patient care in NSCLC management
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None